Tratamento da esclerose múltipla com células tronco: benefícios, desafios e futuro
DOI:
https://doi.org/10.55892/jrg.v7i15.1714Keywords:
Benefits, Stem cells, Challenges, Multiple Sclerosis, FutureAbstract
Multiple sclerosis (MS) is a progressive and chronic neurological disease of the central nervous system, characterized by demyelination, axonal damage, and inflammation. Recently, a cell therapy treatment proposal has emerged through autologous hematopoietic stem cell transplantation (AHSCT) and mesenchymal stem cells (MSCs). In this context, the present study aimed to evaluate the use of hematopoietic and mesenchymal stem cells in the treatment of multiple sclerosis and to identify the short- and long-term benefits of the treatment, as well as the patients' quality of life. Twenty articles were analyzed, selected from searches in the databases (Virtual Health Library, Google Scholar, PubMed, SciELO, and EbscoHost). The results revealed various benefits of cell therapy, including improved quality of life, immunological benefits, and myelin regeneration, especially in patients with relapsing-remitting MS (RRMS), as well as potential adverse effects. AHSCT promotes autoimmune suppression and immunological restoration, while MSCs have regenerative and neuroprotective actions. It is concluded that cell therapy shows promise for the future due to its benefits, although further studies are needed to expand its clinical application.
Downloads
References
ALANAZI, A. et al. Mesenchymal stem cell therapy: A review of clinical trials for multiple sclerosis. Regenerative Therapy, v. 21, p. 201–209, dez. 2022.
BEZERRA, L. M. R. et al. Esclerose múltipla - abordagens diagnósticas e terapêuticas: uma revisão bibliográfica. RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218, v. 5, n. 2, p. e524950, 2024
BROWN, C. et al. Neural stem cells derived from primitive mesenchymal stem cells reversed disease symptoms and promoted neurogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Stem Cell Research & Therapy, v. 12, n. 1, 9 set. 2021.
CASTRO, P. et al. Avanços em terapias modificadoras da doença na esclerose múltipla. A.R International Health Beacon Journal (ISSN 2966-2168), v. 1, n. 5, 2024.
DAS, J. et al. Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with “aggressive” multiple sclerosis. Multiple Sclerosis Journal, p. 1198-1204, 10 fev. 2021.
EDUARDA, M. et al. Terapias Emergentes na Esclerose Múltipla: Perspectivas e Futuro. Brazilian Journal of Implantology and Health Sciences, v. 5, n. 5, p. 4828–4841, 7 dez. 2023.
GENCHI, A. et al. Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study. Nature Medicine, v. 29, n. 1, p. 75–85, jan. 2023.
ISLAM, M. A. et al. Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, v. 12, n. 19, p. 6311, 1 jan. 2023.
LEVADA, L. P. et al. Uma revisão narrativa da literatura sobre o tratamento da esclerose múltipla. Brazilian Journal of Implantology and Health Sciences, v. 6, n. 2, p. 1785–1796, 20 fev. 2024.
NABIZADEH, F. et al. Autologous Hematopoietic Stem-Cell Transplantation in Multiple Sclerosis: A Systematic Review and Meta-Analysis. Neurology and Therapy, v. 11, n. 4, p. 1553–1569, 28 jul. 2022.
NERY, L. G. et al. Therapeutic options for the treatment of multiple sclerosis. Research, Society and Development, [S. l.], v. 11, n. 4, p. e7811426331, 2022.
OLIVEIRA, J. C. de et al. Esclerose múltipla: fisiopatologia, diagnóstico, tratamentos e impacto na qualidade de vida . Brazilian Journal of Health Review, [S. l.], v. 7, n. 4, p. e72161, 2024.
PAGE, M. J. et al. PRISMA 2020 Explanation and elaboration: Updated Guidance and Exemplars for Reporting Systematic Reviews. BMJ, v. 372, n. 160, 29 mar. 2021.
PETERSON, S. et al. Updates on efficacy and safety outcomes of new and emerging disease modifying therapies and stem cell therapy for Multiple Sclerosis: A review. Multiple Sclerosis and Related Disorders, v. 68, p. 104125, dez. 2022.
PETROU, P. et al. Long-Term Clinical and Immunological Effects of Repeated Mesenchymal Stem Cell Injections in Patients With Progressive Forms of Multiple Sclerosis. Frontiers in Neurology, v. 12, 31 maio 2021.
RODRIGUES, F. DE A.; OH, H. Esclerose múltipla e tratamentos. Multiple sclerosis and treatments. Revista Científica Cognitionis, v. 4, n. 2, 10 out. 2021.
SILVA et al. Terapia com células tronco hematopoiéticas colhidas do cordão umbilical em doenças neurológicas. Contemporânea, v. 4, n. 1, p. 3003–3021, 26 jan. 2024.
TOLF, A. et al. Experiences of being treated with autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: A qualitative interview study. PLoS ONE, v. 19, n. 2, p. e0297573–e0297573, 7 fev. 2024.
VISWESWARAN, M. et al. Sustained immunotolerance in multiple sclerosis after stem cell transplant. Annals of Clinical and Translational Neurology, v. 9, n. 2, p. 206–220, fev. 2022.
WILLISON, A. G. et al. The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis. Journal of Neurology, 11 abr. 2022.
ZARIPOVA, L. N. et al. Mesenchymal Stem Cells in the Pathogenesis and Therapy of Autoimmune and Autoinflammatory Diseases. International Journal of Molecular Sciences, v. 24, n. 22, p. 16040, 7 nov. 2023.
